InspireMD, Inc. announced its support for the Centers for Medicare and Medicaid Services (CMS) final National Coverage Determination (NCD) which expands coverage of carotid artery stenting (CAS) and transcarotid artery revascularization (TCAR) to include both symptomatic and standard risk patients. This decision offers a new treatment alternative to patients and their treating physicians and, the company believe, will accelerate the ongoing shift toward an endovascular 'stent first' approach and away from more invasive surgery, the current standard of care.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2 USD | +4.44% | -4.31% | -28.83% |
Mar. 06 | Transcript : InspireMD, Inc., Q4 2023 Earnings Call, Mar 06, 2024 | |
Mar. 06 | Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M | MT |
1st Jan change | Capi. | |
---|---|---|
-28.83% | 46.85M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- NSPR Stock
- News InspireMD, Inc.
- InspireMD, Inc. Supports CMS? Final National Coverage Determination Expanding Coverage of Carotid Stenting to Include Both Asymptomatic and Standard Risk Patients